<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3425">
  <stage>Registered</stage>
  <submitdate>21/12/2011</submitdate>
  <approvaldate>21/12/2011</approvaldate>
  <nctid>NCT01506895</nctid>
  <trial_identification>
    <studytitle>A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema</studytitle>
    <scientifictitle>A Phase 2, Multi-national, Multi-centre, Double Masked, Randomised, Placebo Controlled, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Darapladib Administered for 3 Months to Adult Subjects With Diabetic Macular Edema With Centre Involvement</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>115403</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Retinopathy, Diabetic</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - darapladib
Treatment: drugs - placebo

Experimental: darapladib - darapladib dosed at 160 mg once daily

Placebo Comparator: placebo - Placebo to match once daily


Treatment: drugs: darapladib
Experimental compound 160 mg dose

Treatment: drugs: placebo
Placebo to match

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in Visual Acuity as measured by ETDRS BCVA - Mean change from baseline in ETDRS Best Corrected Visual Acuity (BCVA) after 3 months of treatment</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in Spectral Domain Optical Coherance Tomography - Mean change from baseline in SD-OCT after 3 months of treatment</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Retinal Anatomy - Changes in retinal anatomy as assessed by fluorescein angiography and fundus photography and SD-OCT in the study eye</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and Tolerability as assessed by change from baseline in outcome measures - Safety and tolerability as assesed by: change from baseline in blood pressure and heart rate; assessed by change from baseline in complete ophthalmic exam and visual acuity; assessed by change from baseline in clinical laboratory tests; assessed by change from baseline in the collection of adverse events</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Pharmacodynamic LP-PLA2 enzyme inhibition - Changes over 3 months in the study of LP-PLA2 Enzyme inhibition as data permit</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peak plasma concentration (Cmax) of study drug - Plasma Pharmacokinetic parameters of darapladib as data permit</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration versus time curve (AUC) of study drug - Plasma Pharmacokinetic parameters of darapladib as data permit</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  A female subject is eligible to participate if she is of: Non-childbearing potential
             or child-bearing potential and agrees to contraception for an appropriate period of
             time

          -  Diagnosis of diabetes mellitus (type 1 or type 2)

          -  Confirmation of DME in the study eye by angiography

          -  Confirmation of retinal thickening in the study eye by study doctor

          -  Best corrected visual acuity score of 78-24 letters in the study eye</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Additional eye disease in the study eye that could compromise study assessments

          -  Intraocular surgery, or laser photocoagulation in the study eye within 3 months of
             dosing

          -  Uncontrolled intraocular pressure in the study eye despite treatment with glaucoma
             medication

          -  Uncontrolled diabetes

          -  Certain types of liver disease

          -  Severe reduction in kidney function OR removal of a kidney OR kidney transplant

          -  Blood pressure higher than normal despite lifestyle changes and treatment with
             medications

          -  Certain medications that may interfere with the study medication or eye assessments
             (these will be identified by the study doctor)

          -  Current severe heart failure

          -  Severe asthma that is poorly controlled with medication

          -  Previous severe allergic reaction to food, medications, drink, insect stings, etc

          -  If both birth parents are at least 50% Japanese, Chinese, or Korean ancestry, must
             have a blood sample collected for Lp-PLA2 activity. Those with Lp-PLA2 activity less
             than or equal to 20.0 nmol/min/mL are excluded

          -  Recent participation in a study of an investigational medication

          -  Any other reason the investigator deems the subject should not participate in the
             study

          -  Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>54</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>GSK Investigational Site - Parramatta</hospital>
    <hospital>GSK Investigational Site - Sydney</hospital>
    <hospital>GSK Investigational Site - East Melbourne</hospital>
    <hospital>GSK Investigational Site - Nedlands</hospital>
    <postcode>2150 - Parramatta</postcode>
    <postcode>2000 - Sydney</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Glostrup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Wuerttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to characterize the systemic and ocular safety and tolerability,
      pharmacokinetics, exploratory efficacy and pharmacodynamics of 3 months of repeat
      administration of oral darapladib in diabetic macular edema patients with centre involvement.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01506895</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>